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List of abbreviations 
 
AE: adverse event 
AVNRT: atrio-ventricular node reentry tachycardia 
AVRT: atrio-ventricular reentry tachycardia 
CI: coupling interval 
CIED: cardiac implantable electronic device 
CL: cycle length 
CP: coupled pacing 
CRF: chronic renal failure 
CRT-D: cardiac resynchronization therapy defibrillator 
CRT-P: cardiac resynchronization therapy pacemaker 
CTI: cavo-tricuspid isthmus 
DC-ICD: dual-chamber implantable cardioverter defibrillator 
ERP: effective refractory period 
HF: heart failure 
HRA: high right atrium 
HTX: heart transplantation 
ICD: implantable cardioverter defibrillator 
MPR: mechanical pulse rate 
MVGT: maximum voltage guided ablation technique 
LVEF: left ventricular ejection fraction 
NYHA: New York Heart Association 
PJRT: paroxysmal junctional reciprocating tachycardia 
PP: paired pacing 
PVC: premature ventricular complex 
RF: radiofrequency 
RVA: right ventricular apex 
SC-ICD: single-chamber implantable cardioverter defibrillator 
VNS: vagal nerve stimulation 
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1. Introduction 
Both supraventricular and ventricular arrhythmias are prevalent in patients suffering 
from chronic systolic heart failure (HF), and their impact on mortality and quality of life 
is significant. Besides the well-established treatment with complex, optimised 
pharmacological therapy, promising non-pharmacological methods have been emerged 
in the past decades as frontline therapies: catheter ablation of cardiac arrhythmias and 
utilisation of cardiac implantable electronic devices (CIEDs). Many of them have 
already been clinically proved to be effective not only in treating and preventing 
tachyarrhythmias, but also in reducing morbidity and mortality.  
The spectrum of tachyarrhythmias in patients suffering from chronic systolic heart 
failure is as broad as in the normal population: atrio-ventricular node reentry 
tachycardia (AVNRT), atrio-ventricular reentry tachycardia (AVRT), ectopic and 
reentrant atrial tachycardias, non-reentrant junctional tachycardias, atrial flutter, atrial 
fibrillation, premature ventricular complexes (PVCs), and different sorts of ventricular 
tachycardias are all can be found in heart failure patients. Nevertheless, the distribution 
of these arrhythmias shows some heart-failure and age-related variability. For example 
AVRT, paroxysmal junctional reciprocating tachycardia (PJRT), junctional ectopic 
tachycardia have a strong predilection in childhood (Ko et al. 1992, Coumel P et al. 
1967), whereas atrial fibrillation is predominantly the arrhythmia of adulthood and its 
likelihood is growing with advanced age, as it became evident from the sub-analysis of 
the Framingham study (Kannel WB et al. 1982). Well-known fact, that malignant 
ventricular arrhythmias and sudden cardiac death are far more common in systolic heart 
failure, especially in patients suffering from post-infarction ischemic cardiomyopathy 
(Myerburg et al. 1992). The prevalence of atrial fibrillation is also considerably higher 
in congestive heart failure (Fabbri G et al. 2012). 
 
1.1. Supraventricular arrhythmias 
In the non-pharmacological treatment of supraventricular tachyarrhythmias catheter 
ablation techniques are impressively effective, therefore they have a primary role over 
CIEDs. Catheter ablation therapy of the common supraventricular arrhythmias in heart 
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failure is not much different from the standard approach. AVNRT, AVRT, AV-node 
ablation, cavo-tricuspid isthmus (CTI) ablation, and pulmonary vein isolation requires 
the same technical setup as in otherwise healthy patients. What can make these cases 
more challenging are the abnormal anatomy and the usually enlarged cardiac chambers 
and dilated tricuspid and mitral annuli. The atria in chronic systolic heart failure are 
dilated due to the elevated end-diastolic pressures and dilated cardiomyopathy usually 
causes annular dilatation which can promote significant functional valvular 
regurgitation. All of these pathologic variations can make manual catheter manipulation 
and effective energy delivery even more difficult (Ren JF et al. 1998), frequently 
requiring intracardiac ultrasound guidance and the use of long-sheaths to give sufficient 
support to the ablation-catheter.  
 
Another important aspect of the ablation procedure is time. Patients suffering from heart 
failure can hardly tolerate long sessions and sometimes considerable amount of saline-
overload without dyspnoea while lying supine on the table. Therefore every attempt to 
shorten procedure time without compromising success is welcomed. This can be 
achieved with single-shot devices like the cryoballon (Sarabanda AV et al. 2005) or the 
phased-array duty-cycled ablation device (Boersma LV et al. 2008) in pulmonary vein 
isolation of atrial fibrillation ablation, or with the maximum-voltage guided technique 
of CTI ablation performed in sinus rhythm (Redfearn DP et al. 2006). Ablation time, 
procedure time and success rate were compared using the maximum-voltage guided 
technique during ongoing isthmus-dependent atrial flutter in our work. 
 
The impact of atrial fibrillation ablation on long term clinical endpoints and mortality is 
under investigation. The ongoing CASTLE-AF (Marrouche NF et al. 2009), and RAFT- 
AF trials are recruiting patients suffering from chronic heart failure. The results are due 
in 2016 and awaited with excitement, since no pharmacologic rhythm control strategy 
was proved to be superior over rate control both in preserved (AFFIRM: mean left 
ventricular ejection fraction (LVEF) 54.7% – Wyse DG et al. 2002), and in depressed 
left ventricular function (AF-CHF: mean LVEF 27.6% – Roy D et al. 2008). Results of 
some nonrandomized studies and a small randomized single-centre trial (ARC AF - 
Jones DG et al. 2013) that recruited heart failure patients who underwent successful 
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radiofrequency (RF) ablation for persistent atrial fibrillation are promising in terms of 
improved cardiopulmonary exercise capacity and quality of life when comparing them 
to the pharmacological rate control strategy.  Results of atrial fibrillation ablation were 
compared between groups of congestive heart failure and normal systolic function in an 
early prospective trial conducted by the Bordeaux group (Hsu LF et al. 2004).  They 
reported significant improvement not only in symptoms and exercise capacity, but also 
in ejection fraction. Assessing differences in mortality was beyond the scope of all these 
small studies. Nevertheless, these results may give rise to the speculation that rhythm 
control achieved by catheter ablation could have a priority over cumbersome 
antiarrhythmic drug therapy with its well-known and feared proarrhythmic effects. 
Catheter ablation of paroxysmal or persistent atrial fibrillation (i.e. non-pharmacological 
rhythm control) in heart failure proved to be superior when it was compared to the 
“ablate and pace” strategy of rate control. This was demonstrated in the randomized, 
multicenter PABA-CHF trial (Khan MN et al 2008). Not only the composite endpoint 
(LVEF, 6-minute walk test, and quality of life score), but also LVEF alone was 
significantly higher in the pulmonary vein isolation group in the end of the 6-month 
follow-up period (35 vs. 28 % p<0.001). Of note, there was no improvement in ejection 
fraction in the “ablate and pace” group. This is quite embarrassing given the fact that the 
pacing method used was biventricular regarding the baseline mean LVEF of 29%, and 
in the previously conducted PAVE trial biventricular pacing proved to be superior over 
conventional right ventricular apical pacing after complete AV-node ablation in a group 
of patients with a mean LVEF of 47% (Doshi RN et al. 2005). 
 
Device therapy can also have a promising new role in atrial fibrillation rate control. 
Rate control of rapid ventricular response can be achieved by AV-conduction slowing 
drugs or in drug-refractory cases, by AV-node catheter ablation with prior pacemaker 
implantation. The recommended pacemaker is preferably a biventricular system in 
systolic heart failure (Brignole et al. 2013) if we consider the almost 100% pacing ratio 
after AV-nodal ablation. Our group has tested two similar ventricular pacing methods to 
instantly control the mechanical pulse rate: coupled pacing and paired pacing.   
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1.2. Ventricular arrhythmias 
In the non-pharmacological treatment of ventricular arrhythmias both CIEDs and 
catheter ablation techniques have a firm ground in heart failure. The landmark 
randomized trials on implantable cardioverter defibrillator (ICD) implantation for 
secondary prevention of sudden cardiac death due to malignant ventricular arrhythmias 
were done in the end of the nineties of the past century. The AVID trial (Zipes DP et al. 
1997), the CASH trial (Kuck KH et al.2000) and the CIDS trial (Connolly S et al. 2000) 
proved first that ICDs decrease relative mortality by 20-33% in patients with impaired 
systolic function (mean LVEF were 32%, 46%, and 33%, respectively), as compared 
with antiarrhythmic therapy only. Both ischemic and non-ischemic cardiomyopathy 
patients benefited from ICD implantation, although sometimes in a statistically non-
significant manner.  
Not much later, larger trials were conducted in the field of primary prevention of sudden 
cardiac death of coronary patients with results of relative mortality reduction in a 
magnitude of 23-51% (SCD-HeFT – Bardy G et al. 2005; MADIT-II – Moss AJ et al. 
2002 ; MUSTT – Buxton AE et al. 1999). In the DEFINITE trial (Kadish A et al. 2004) 
ICDs reduced the rate of sudden death from arrhythmia in non-ischemic 
cardiomyopathy significantly by 80%, while all-cause mortality reduction was non-
significant. With the results of the DINAMIT (Hohnloser S et al. 2004) and IRIS 
(Steinbeck G et al. 2009) trials it became clear that primary prevention ICD 
implantation within 30-40 days of an acute coronary event complicated with depressed 
systolic function did not reduce long-term mortality. It is of note, however, that 
arrhythmic mortality decreased in both trials in a significant manner, but this gain was 
offset by the rate of non-arrhythmic deaths. To our current knowledge, only ICD 
implantations performed more than 40 days after myocardial infarction carry favourable 
clinical outcomes.  
Since 1994, when Serge Cazeau and his colleagues performed the first biventricular 
device implantation (which was originally a four-chamber system, the left ventricular 
lead was implanted epicardially and the coronary sinus was used to place the left atrial 
lead: Cazeau S et al. 1994), cardiac resynchronisation therapy (CRT) has emerged as an 
effective tool in the treatment of advanced heart failure in patients with systolic 
dysfunction, wide QRS complex, and on optimal medical therapy. Besides improving 
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quality of life, ejection fraction, exercise tolerance and reducing heart failure-related 
symptoms, cardiac resynchronisation therapy pacemaker (CRT-P) added on top of 
optimal medical therapy could significantly reduce mortality as the landmark CARE-HF 
trial proved it (Cleland JG et al. 2005). Relative mortality reduction was 36% at 29 
months, and this study also detected a decreased number of sudden death with CRT-P 
(9.4 % on optimal medical therapy vs. 7.1 % on CRT-P). This could also be attributed 
to the improvement in left ventricular systolic function. Because the target population 
for CRT inherently has poor left ventricular ejection fraction, combining CRT with an 
ICD for primary prevention became almost a must in the developed world, especially 
after the results of the COMPANION trial (Bristow MR et al. 2004). This trial showed 
some incremental benefit of cardiac resynchronisation therapy with defibrillator (CRT-
D) over CRT-P in relative all-cause mortality reduction (a secondary end-point variable) 
against medical therapy-only (36% vs.24%). It is of note, however, that this trial was 
not primarily designed to directly compare CRT-P with CRT-D, so its conclusions refer 
strictly to the primary goal: comparison of CRT (with and without ICD) versus optimal 
medical therapy alone, and the authors correctly concluded at the end of their paper, that 
the choice between CRT-P or CRT-D should be made individually according to the 
particular clinical case (Bristow MR et al. 2004).  In low symptomatic New York Heart 
Association (NYHA) I-II patients with an ejection fraction below 30%, CRT-D reduced 
the combined end-point of all-cause mortality or a heart-failure event by 34% versus 
ICD-alone according to the MADIT-CRT trial (Moss AJ et al. 2009). There was no 
significant mortality reduction in this trial. Similar results were reported in the RAFT 
trial conducted on NYHA II-III patients, with 25% relative reduction in the combined 
primary end-point of death or hospitalization for heart failure (Tang AS et al. 2010). 
Moreover, this latter trial showed a significant risk reduction in all-cause mortality 
(25%), and in the subgroup analysis this remained true even for NYHA II patients. 
 
Considerable hemodynamic improvement assessed by Doppler echocardiography after 
initiation of biatrial pacing in patients with interatrial conduction block, called “atrial 
resynchronization” was enthusiastically reported in a paper as a single-centre experience 
(Daubert JC et al. 2004). Here the right atrial lead was placed in the conventional way in 
the appendage, and an additional left atrial lead was placed far out in the coronary sinus. 
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The potential additive benefit of interatrial resynchronization in cardiac 
resynchronization therapy has not gained wide acceptance in everyday clinical practice. 
 
The above-mentioned strong results of ICD and CRT trials and the accumulating 
experience of the implanting centres published as single-centre studies have been 
embedded in the recommendations of the current international guidelines on treating 
ventricular arrhythmias (Zipes DP et al. 2006), device therapy (Epstein AE et al. 2013), 
and the 2013 cardiac pacing and resynchronization therapy guideline (Brignole M et al. 
2013). Most ICD and CRT-P/D indications are backed with an A or B level of evidence. 
Patient selection for CRT continuously refines as new data regarding the impact of 
comorbid conditions on survival come into the limelight. The most striking example is 
the unfavourable outcome with non-left bundle branch block in the subgroup analysis of 
the MADIT-CRT study. But other comorbidities as pulmonary hypertension, extreme 
left ventricular dilatation, and chronic renal failure are getting more attention even at the 
guideline level (Brignole et al. 2013). The role of chronic renal failure was addressed by 
our work in a series of 60 CRT patients. 
 
On the downside of ICD therapy are the device-related complications and inappropriate 
ICD discharges. As the number of implantations exponentially rises, the absolute 
number of lead-related complications is also rising steeply, causing more need for 
complex extraction procedures. Insulation damage, conductor fracture, externalisation, 
dislodgement, and cardiac perforation are some of the mechanisms of ICD lead-related 
complications (Borleffs CJ et al. 2009). Implantation of an ICD is common for non-
hospitalized patients awaiting heart transplantation (Sandner SE et al. 2001), and those 
ICD systems are usually totally explanted during the transplantation procedure. 
Complication rates and possible causes of the failure of total surgical system 
explantation during heart transplantation were addressed by our work in Rotterdam. 
 
CRT is only effective in patients with wide-QRS complexes, especially of left bundle 
branch block morphology. In fact, the greater proportion of heart failure patients has 
narrow QRS complexes therefore an effective and safe device-based therapy targeting 
this population would be of high clinical importance. Vagal nerve stimulation (VNS) 
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has been traditionally used in drug refractory epilepsy, but its use in congestive heart 
failure has been investigated in the last few years as it effectively reduces heart rate and 
increases heart rate variability. Although the concept of the human cervical vagal 
stimulation system is not new (US patent in 2001), the first in-man study was reported 
only in 2008 by Schwartz and colleagues. The system was well-tolerated and VNS 
improved NYHA class, quality of life and decreased left ventricular end-systolic 
volume during 6 months in 8 patients (Schwartz PJ et al. 2008). In 2011 the CardioFit 
Multicenter Trial showed similarly promising results in 32 patients after 6 months with 
an improvement in LVEF from 22+7 to 29+8%, although this came with the expense of 
numerous serious adverse events (40.6%) and non-negligible side-effects as death 
(3/32), pulmonary oedema, surgical complication, and stimulation pain (De Ferrari GM 
et al. 2011). Results of the NECTAR-HF study (NYHA class II-IV, LVEF <35%, on 
optimal medical therapy, right sided VNS, 96 patients) did not evidence any significant 
improvement in LVEF or a reduction in brain-natriuretic peptide levels at 6 months, 
although quality of life was improved in the actively treated group (presented at ESC 
Congress 2014, Barcelona by Zannad F). The ANTHEM-HF trial (NYHA class II-III, 
LVEF <40%, optimal medical therapy, right or left sided VNS, 60 patients) had 
somewhat better results as LVEF improved significantly in 6 months (presented at ESC 
Congress 2014, Barcelona by Anand IS). The average stimulation current applied in this 
study was somewhat higher than that in the NECTAR-HF (2.0 vs 1.4 mA, respectively).  
Noteworthy, none of these trials were designed to assess hard clinical end-points. 
 
Catheter ablation of outflow tract ventricular arrhythmias can be as effective in heart 
failure patients as in normal subjects. The technical setup, procedure, and endpoints are 
just the same. Left ventricular systolic function can improve considerably after outflow 
tract ablation in patients with frequent monomorphic PVCs. Navigation to the site of 
origin of PVCs can be challenging, and in the minority of cases the substrate can only 
be localised with epicardial mapping via the coronary sinus or via direct subxyphoid 
epicardial access (Abraham P, Abkenari LD et al. 2013). In difficult-to-reach areas 
remote magnetic navigation can help steer the catheter to the right spot and maintain 
reliable catheter contact: both are key factors of a successful and safe ablation procedure 
(Schwagten B et al. 2009).  
DOI:10.14753/SE.2015.1816
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A considerable proportion of heart failure patients suffer from post-infarction ischaemic 
cardiomyopathy. Infarct scar-related macroreentry ventricular tachycardias are 
characteristic arrhythmias of this population. Nevertheless, scar-related ventricular 
arrhythmias are also well known in other diseases as dilated cardiomyopathy, Chagastic 
disease, arrhythmogenic right-ventricular cardiomyopathy, and cardiac sarcoidosis. 
Catheter ablation of a ventricular tachycardia in a patient suffering from heart failure is 
a rather challenging task both intellectually and manually and requires seamless team-
work. The introduction of substrate mapping (Marchlinsky FE et al. 2000) and the use 
of open irrigated tip ablation catheters gave a boost to ventricular tachycardia ablation. 
Multicenter studies like the Thermocool Ventricular Tachycardia Ablation trial 
(Stevenson WG et al. 2008) or the Euro-VT trial (Tanner H et al. 2010) conducted in 
experienced, large-volume sites presented promising results on acute success rates 
(81%), and on the reduction of ICD shock burden, but moderate success on the 6-month 
arrhythmia-free survival (53%, 51 %). These studies indicate that high recurrence rates 
(51%, 49 %) still remain an issue to deal with. Because frequent ICD discharges are not 
only painful, causing significant discomfort and psychological stress to patients, but are 
also independent predictors of adverse clinical outcomes, techniques to reduce 
avoidable appropriate and inappropriate ICD shocks are increasingly become part of the 
modern anti-tachycardia management (Israel CW 2008). Preventive substrate-based 
ablation of the left ventricular scar in post-infarction patients considerably reduced ICD 
discharges, as it has been straightforwardly demonstrated by the SMASH-VT trial 
investigators (Tung R, et al. 2010). These studies also imply that ICDs and 
antiarrhythmic drug therapy still remain in the mainstream of ventricular tachycardia 
management. 
 
Bundle-branch ventricular tachycardias are common in dilated cardiomyopathy with 
41% incidence, and sometimes after surgical aortic valve replacement (Caceres J et al. 
1989). Fast rates, poor haemodynamic tolerance and bundle-branch block QRS pattern 
similar to sinus rhythm are quite characteristic of these tachycardias. Catheter ablation 
of the conduction system (mainly the right bundle) can cure the arrhythmia with nearly 
100 % success even without the use of sophisticated three-dimensional electro-anatomic 
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mapping systems. Although curative bundle-branch ventricular tachycardia ablation 
could be a promising perspective, leaving the patient without an ICD carries a non-
negligible risk, and future malignant arrhythmias are not uncommon if we consider the 
underlying cardiac disease. (Lopera G et al. 2004) 
 
1.3. Tachycardia-induced cardiomyopathy 
An evergreen aspect of the arrhythmia-heart failure relationship is the chicken-or-egg 
question of causality. Not only the malfunctioning heart can be more susceptible of 
even life-threating arrhythmias but also some forms of supraventricular and ventricular 
tachyarrhythmias can deteriorate left ventricular systolic function considerably, causing 
a special form of heart failure called tachycardia-induced cardiomyopathy. By 
definition, this is a cardiomyopathy with left ventricular dilation and systolic 
dysfunction in the absence of other causative structural heart disease, and myocardial 
function recovers after termination of the arrhythmia (Packer DL et al. 1986). The 
incidence of tachycardia-induced cardiomyopathy was 2.7 % in a group of 625 patients 
with congestive heart failure referred for catheter ablation. (Donghua Z et al. 2013). 
Among atrial tachyarrhythmias incessant forms of focal atrial tachycardia (Medi C et al. 
2009), PJRT (Dorotskar et al. 1999), atrial flutter (Pizzale et al. 2009), and atrial 
fibrillation with rapid ventricular conduction (Grogan M et al. 1992) are the most 
common forms causing tachycardia-induced cardiomyopathy. Males, young patients 
with incessant forms of atrial tachycardias are more susceptible of developing 
tachycardia-induced cardiomyopathy in focal atrial tachycardias (Medi C et al. 2009). It 
is interesting that not only ventricular rate matters but also rhythm irregularity and 
longer atrial cycle lengths can contribute to the development of this cardiomyopathy, 
and hence a reliably predictive threshold in heart rate does not exist. Even an arrhythmia 
other than a true tachycardia can cause systolic dysfunction. Frequent PVCs with a 24-
hour burden of more than 20-24% (Takemoto M et al. 2005, Baman TS et al. 2010) or 
with a >10.000/day absolute number (Kanei Y et al. 2008) can considerably decrease 
left ventricular ejection fraction, and can lead to heart failure on the long run. These 
PVCs mostly arise from the outflow tracts of the ventricles or from the valve cusps, and 
can be ablated safely and effectively with success rates reaching 90%. Medical 
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treatment or ablation of the substrate of these arrhythmias can restore not only sinus 
rhythm but also left ventricular systolic function, usually within some weeks or months 
(Takemoto M et al. 2005, Vijgen J et al. 1997, Hasdemır C et al. 2013). 
 
1.4. Remote CIED monitoring and patient management 
What CIEDs can undoubtedly add to the improvement of standards in heart failure 
management are their extensive arrhythmia- and heart failure-related diagnostic 
functions combined with remote follow-up and remote monitoring capabilities. These 
features include -among many others- monitoring and trending lead and generator 
integrity, atrial and ventricular arrhythmia burden, patient activity, mean heart rate, 
heart rate variability, pulmonary artery and left atrial pressures, and intrathoracic 
impedance changes to monitor possible thoracic fluid accumulation. Similarly to the old 
clinical observation, the onset of a persistent atrial arrhythmia can lead to heart failure 
more frequently (relative risk 65%) which is heralded by a decrease in thoracic 
impedance indicating fluid accumulation, and vice versa: significant intrathoracic 
impedance drops are followed by new-onset atrial fibrillation with a relative risk of 32 
percent over 30 days (Andriulli JA et al. 2014). The really innovative point in the 
CIED-based remote management is to forecast impending clinical deterioration and to 
response earlier than a routine in-office visit would take place, and before disease 
progression would lead to hospitalisation.  The body of evidence of remote management 
is growing regarding its safety, utility and long-term positive impact on patient 
outcomes. The results of the impressively large North American ALTITUDE registry 
(remotely/standard monitored: 69.556/116.222) showed a striking 50 percent relative 
mortality risk reduction and long-term survival benefit in remotely monitored ICD 
patients (Saxon LA et al. 2010). When the information gained from remote monitoring 
of an ICD or CRT-D system was incorporated into a clinical response-system, earlier 
therapy decision and intervention could prevent further clinical deterioration, and the 
length of hospital stay due to a cardiovascular event was significantly shorter for 
patients in the remote monitoring arm. This was indicated by the results of the 
CONNECT trial (Crossley GH et al. 2011), and more recently by the IN-TIME study, 
where a significant difference in the modified Packer score (27.2% vs 18.9%; p<0.05) 
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and all-cause mortality (8.7% vs 3.4%; P<0.01 ; p< 0.012) was observed in favour of 
the telemonitored cohort after 12 months follow-up (Hindricks et al. 2014).  The content 
of telemonitored data prompted clinician contact with 76% of the patients. Data from 
the COMPAS (Mabo P et al. 2012) and ECOST trials (Guedon-Moreau et al. 2013) 
showed that telemonitoring of both conventional pacemaker systems and ICDs is safe, 
reduces the annual number of in-office visits, and telemonitoring-based patient 
management could substantially decrease (70% relative reduction) the number of 
appropriate and inappropriate ICD shocks in the remotely monitored arm of the ECOST 
study. Yearly in-office follow-up of primary prevention ICD systems is as safe as 
quarterly checking, and it is mutually beneficial for the patient and for the caregiver as it 
improves quality of life and significantly decreases the in-office follow-up burden of the 
outpatient clinics according to the results of the REFORM trial (Hindricks et al. 2014). 
As a consequence, the current European guideline on cardiac pacing endorses remote 
monitoring with an IIa recommendation (Brignole et al. 2013). 
Another interesting remote monitoring target is implantable hemodynamic monitoring. 
In the CHAMPION trial a wireless pulmonary artery pressure monitor delivered via 
right heart catheterisation was tested. Remote monitoring-guided timely patient 
management with diuretics or long-acting nitrates to reach targeted pulmonary arterial 
pressure values (mean pressure 10-25 Hgmm) yielded in a 37% relative risk reduction 
in heart failure hospitalizations (Abraham WT et al. 2011). A transvenously implanted 
pressure sensor lead capable of directly monitoring left atrial pressure changes on the 
interatrial septum is under clinical investigation. Both kinds of sensors are powered 
wirelessly from an external patient interface unit.  
 
1.5. Instantaneous rate-control of rapid atrial fibrillation with coupled 
and paired ventricular pacing 
 
Atrial fibrillation is the most common sustained cardiac arrhythmia and its prevalence 
keeps increasing worldwide. Because the arrhythmia is often asymptomatic the true 
prevalence is likely even higher (Camm AJ et al. 2010). When it is not possible or not 
reasonable to restore sinus rhythm, ventricular rate control is the option to alleviate 
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symptoms and to prevent the development of heart failure associated with rapid 
ventricular rates. The efficacy of the available pharmacological agents to control the 
ventricular rate during permanent atrial fibrillation is limited and in some cases non-
pharmacological methods such as atrioventricular nodal ablation and implantation of a 
permanent pacemaker are necessary.  
 
Premature activation of the heart results in impaired contraction and randomly occurring 
ventricular ectopic activations can prolong the compensatory pause during atrial 
fibrillation. Based on this observation the concept of coupled pacing (CP) in rapid atrial 
fibrillation has been developed (Lau CP et al. 1990) and was revisited recently to 
improve cardiac function by controlling ventricular rate (Yamada H et al. 2006). CP 
consists of premature electrical stimulation delivered shortly after the effective 
refractory period (ERP) of the sensed ventricular activation, resulting in electrical 
activation but no mechanical contraction. The concealed ventriculoatrial conduction 
caused by the extrastimulus can prolong the conducted RR interval in atrial fibrillation, 
and thus decrease the mechanical pulse rate (MPR). When pairs of stimuli are applied 
and the second stimulus is placed shortly after the ERP of the first one, minimal or no 
mechanical contraction occurs (Frommer PL et al. 1966). During this paired pacing (PP) 
the first stimulus of each pair results in an augmented contractile response by post-
extrasystolic potentiation and can increase the cardiac output in heart failure patients 
(Braunwald E et al. 1964, Cooper MW et al. 1986). As rapid paroxysmal atrial 
fibrillation can lead to symptomatic heart failure, a non-pharmacological method to 
promptly control the pulse rate of such an episode would be of great clinical 
importance. 
 
1.6. Maximum voltage-guided technique for cavotricuspid isthmus 
ablation during ongoing atrial flutter 
 
Radiofrequency ablation of the CTI is a widely and effectively used procedure in 
patients with counterclockwise or clockwise typical atrial flutter (Cosio FG et al. 1993, 
Kirkorian G et al 1994, Shah DC et al. 1997). Ablation is superior to conventional 
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antiarrhythmic drug treatment (Natale A et al. 2000) because at the end of a 21±11 
month-long follow-up only 36% of patients on antiarrhythmics were in sinus rhythm 
and 63% required rehospitalisation, compared to the 80% and 22% after CTI ablation. 
Pathological studies revealed that the CTI is composed of distinct muscular bundles, 
formed to an isthmus by connective tissue binding them together (DaCosta A et al. 
2004, Cabrera JA et al. 2005).  
In most centres an empiric anatomical approach is performed by drawing a line of 
lesions from the tricuspid annulus to the inferior caval vein until bidirectional 
conduction block is achieved. Although, this approach is highly successful, it might 
require a high number of applications and long procedure times. Recently, an alternative 
approach was developed where large atrial signals were targeted as they represent 
bundles of conduction through the isthmus. This method was tested and was proven to 
be applicable (Redfearn DP et al. 2006, Subbiah RN et al. 2007, Posan E et al. 2007). 
The results are promising in decreasing fluoroscopy and procedure times without 
compromising success rate. The success of this novel method is related to the anatomy 
of the CTI (Figure 1). It seems that the CTI does not appear to be a continuous 
homogenous atrial tissue. Indeed, careful histological examination of the isthmus  
 
 
 
Figure 1 Cavo-tricuspid isthmus anatomy 
Panel A shows the cavo-tricuspid region of the right atrium in a macroscopic anatomic 
specimen. Numbers show the discrete extensions of pectinate muscular bundles forming 
the isthmus. Black arrows highlight the Eustachian valve. Panel B depicts different 
isthmus anatomies. 
IVC: inferior vena cava, CS: coronary sinus, TV: tricuspid valve 
(from Redfearn DP et al. 2006) 
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reveals very variable anatomy (Cabrera JA et al. 2005, DaCosta A et al. 2004, Redfearn 
DP et al. 2006). The length, the shape and some other parameters are very varying. On 
top of that it is clear that the isthmus is not composed of muscle bundles equally 
distributed throughout this region. These muscle fibers rather oriented as discrete 
bundles and pectinate extensions of the crista terminalis (DaCosta A et al. 2004). This 
certainly determines its conduction properties favouring longitudinal conduction over 
these bundles. Based on the hypothesis that these bundles are responsible for the 
conduction of electrical activation, the maximum-voltage guided technique (MVGT) 
was developed and introduced (Ozaydin M et al. 2003, Hall B et al. 2004, Okishige K et 
al. 2005, Redfearn DP et al. 2006). This technique was reported to be a feasible method 
to reach bidirectional isthmus block without the need for a complete anatomic ablation 
line, however all ablation procedures were performed in sinus rhythm or during pacing 
from the coronary sinus (Redfearn DP et al. 2006). Using this ablation technique shorter 
ablation times could be achieved among patients in sinus rhythm according to previous 
reports (Subbiah RN et al. 2007). This was associated with higher mean temperature, 
suggesting better catheter stability. However, this issue was not evaluated in patients 
undergoing CTI ablation during ongoing atrial flutter in a randomized prospective 
fashion. 
 
1.7. Defibrillation coil retention during orthotopic heart transplantation 
An implantable cardioverter-defibrillator has become the standard therapy for patients 
with chronic heart failure at high risk for sudden cardiac death. Therefore it is a 
reasonable choice for non-hospitalized patients awaiting heart transplantation (HTX) 
(Sandner SE et al. 2001). Numerous primary prevention trials conducted on sudden 
cardiac death in chronic heart failure patients have resulted in the expansion of ICD 
indications, thus the number of implanted ICD systems is growing continuously.  
Defibrillation leads are the most vulnerable part of the ICD system, due to their 
complex design and to their need to withstand mechanical strain. Management of 
patients presenting with ICD lead-related adverse events can be very challenging. The 
estimated lead survival rates are 98% at 4 years, 85% at 5 years, and 62 to 60% at 8 
years (Dorwarth U et al. 2003, Kleemann T et al. 2007). Better long-term lead survival 
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rates with 83 % at 10 years were reported when polyurethane and coaxial leads were 
excluded from analysis (Borleffs CJ et al. 2009). Malfunction or failure of ICD leads 
can occur by several mechanisms including dislodgement, cardiac perforation, 
conductor fracture, and insulation damage, some of them may be attributed to lead 
design (Porterfield JG et al. 2009). Malfunctioning, failed, or infected ICD leads require 
lead revision, extraction and/or replacement. The removal of a retained lead fragment 
after a transvenous lead extraction attempt is often possible only via thoracotomy 
(Wilkoff BL et al. 2009). 
 
1.8. Cardiac resynchronisation in chronic renal failure 
 
Cardiac resynchronisation therapy has emerged from the therapeutic options of chronic 
heart failure as an effective tool of treatment over the last two decades. By performing 
CRT in patients who do not adequately respond to optimal pharmacological therapy, 
clinicians can relieve HF symptoms, improve quality of life, and reduce long-term 
mortality (Cleland JG et al. 2005, Bristow MR et al. 2004).  Previous guidelines have 
laid down general indications for CRT as ejection fraction below 35 %, New York 
Heart Association (NYHA) functional class of II-IV, and QRS duration longer than 
120-130 ms (Vardas PE et al. 2007, Epstein AE et al. 2008). Chronic renal failure 
(CRF) is a condition that worsens the clinical course and mortality of HF (Smith GL et 
al. 2006), and data regarding its impact on the success of CRT are sparse in the 
literature. 
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2. Objectives 
2.1. Instantaneous rate-control of rapid atrial fibrillation with coupled 
and paired ventricular pacing  
 
The objective of this study was to compare the acute rate-controlling effects of CP and 
PP algorithms during atrial fibrillation with rapid ventricular rates in humans in an 
experimental setting. We also wanted to determine the drive train cycle length resulting 
in the lowest controlled rate during PP. Safety of the different ventricular pacing 
algorithms were analysed according to their ability to trigger life-threatening 
arrhythmias.  
 
2.2. Maximum voltage-guided technique for cavotricuspid isthmus 
ablation during ongoing atrial flutter  
 
In order to assess the feasibility of the MVGT during ongoing atrial flutter we compared 
procedural outcomes in patients undergoing standard anatomical ablation vs. patients 
with MVGT. The primary endpoints of this prospective randomized study were acute 
and chronic procedural success, fluoroscopy time, and procedure times. Secondary 
endpoints were the number of radiofrequency lesions and total radiofrequency 
application duration. 
 
2.3. Defibrillation coil retention during orthotopic heart transplantation 
 
Surgical removal of the whole ICD system is part of the orthotopic HTX procedure and 
it is usually carried out without complications (Smith MC et al. 2008). We wanted to 
explore the incidence and causes of defibrillation lead-related adverse events in our 
HTX patients who had an ICD implantation while awaiting heart transplantation. We 
collected data on lead retention, conductor fracture, insulation damage, dislodgement, 
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perforation, and lead migration. We compared the incidence of these adverse events 
according to the type of shock lead. 
 
2.4. Cardiac resynchronisation in chronic renal failure 
 
We aimed to assess the effect of CRF on the long-term clinical outcome and mortality 
of patients who underwent CRT implantation at our institute. Clinical outcome 
measures as CRT responder rate, NYHA functional class, LVEF, number of annual 
hospitalizations and mortality were compared between groups with normal and 
abnormal renal function. We also addressed the question whether the more frequent 
utilisation of CRT-D over CRT-P could be transformed to a survival advantage in CRF 
patients. 
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3. Methods 
 
3.1. Instantaneous rate-control of rapid atrial fibrillation with coupled 
and paired ventricular pacing 
Having their informed consent obtained sixteen patients (12 males), scheduled for 
elective pulmonary vein isolation because of paroxysmal or persistent atrial fibrillation, 
were enrolled into this prospective, single-centre study. The study was conducted in the 
Hungarian Institute of Cardiology. All patients had spontaneous atrial fibrillation during 
the procedure as we only selected those patients from the paroxysmal group who had an 
ongoing episode in order to avoid burst-induction of atrial fibrillation on the table. The 
enrolment into the study was not done in a consecutive manner, accordingly. All 
patients were free of angina, pulmonary, or peripheral oedema. 
Electrophysiological studies were performed in the post-absorptive, non-sedated state 
during spontaneous atrial fibrillation. The procedure was done right before the 
pulmonary vein isolation. Standard 5 Fr quadripolar electrophysiological catheters 
(Bard Inc., Lowell, MA, USA) were introduced under fluoroscopic guidance into the 
right ventricular apex (RVA) and high right atrium (HRA) via the right femoral 
approach. An arterial line was inserted into the right radial artery for monitoring arterial 
blood pressure and MPR. Surface electrogram, intracardiac electrograms from the RVA 
and HRA, and arterial pressure were monitored and recorded simultaneously and 
continuously. 
The distal pairs of the electrodes were used to stimulate the right ventricle and the 
proximal pairs to sense spontaneous ventricular signals. The pacing protocol was 
generated using a four-channel Radionics stimulator (Model PACE-1A, Radionics, Inc., 
Burlington, MA, USA). The pulse output was 5 V at 2 ms. Following the measurement 
of the ventricular ERP by ventricular extrastimulus testing, CP or PP was applied in 
random order in each patient. During CP a coupling interval (CI) of ERP plus 20 ms 
was used following a sensed ventricular event (Figure 2). To maintain the steady 
hemodynamic effects of pacing, stimulation protocols were delivered for 3 minutes. 
Paired pacing was started with a basic cycle length of 500 ms followed by an 
extrastimulus with a CI of ERP plus 20 ms. The drive train was then changed at 50 ms 
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increments. Stimulation protocols were separated by 5-minute breaks. The MPR was 
recorded for 3 minutes at each increment until the lowest regular MPR frequency was 
reached. The MPR was analysed under steady-state conditions for all protocols during 
the last minute. Irregularity index of the pulse cycle length (CL) was defined as the ratio 
of (CLmax- CLmin)/CLmax > 0.10. Proarrhythmic effects were characterized by the 
number of PVCs and/or ventricular tachycardia. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2 Initiation of coupled pacing 
Invasive electrophysiological and hemodynamic recordings obtained from a patient 
during atrial fibrillation.  When CP was initiated with a coupling interval of 224 ms, the 
previously fast and irregular mechanical pulse rate became significantly slower and less 
irregular. Time callipers showing arterial pulse cycle lengths before and during CP. 
Arrows point to the diminished electrograms of spontaneous beats on the RVA p (sense) 
channel used for pacing. Registration speed: 100 mm/sec 
Abbreviations: 
I, II, V6: surface ECG recordings; RVA p (sense): pace/sense channel from the 
intracardiac electrode in the right ventricular apex; ABP: radial arterial pressure curve; 
S2, S3: markers of pacing extrastimuli 
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3.2. Maximum voltage-guided technique for cavotricuspid isthmus 
ablation during ongoing atrial flutter  
 
Twenty patients were recruited into this single-centre, prospective, randomized study 
conducted in the Hungarian Institute of Cardiology. Included patients were aged >18 
years, all patients gave their informed consent to the study. The presence of 
cavotricuspid isthmus dependent atrial flutter was proven by the atrial activation 
sequence and concealed entrainment mapping from the CTI during the 
electrophysiological evaluation, with a difference in tachycardia cycle length and post-
pacing interval of less than 30 milliseconds. Patients with prior CTI ablation were 
excluded from the study. The study patients were randomized into two groups. In group 
I (ten patients) CTI block was achieved with a complete, continuous anatomical ablation 
line using standard ablation technique. After completion of the line without termination 
of the flutter or without achievement of bidirectional block (Shah DC et al. 1999, 
Sasano T et al. 2002) another line was performed usually at a more anterior location. 
Mapping for gaps were only performed if the second anatomical line was still 
unsuccessful. In group II (ten patients) the CTI was mapped, and peak-to-peak bipolar 
atrial electrogram amplitudes were measured continuously, and the application points 
were guided by the highest amplitude potentials on the CTI sequentially until 
bidirectional isthmus block was reached (Figure 3).  
In both groups standard pacing manoeuvres were used to verify bidirectional isthmus 
block after the termination of the atrial flutter (Tada H et al. 2002). Cross over to 
another group was not allowed in this study. As part of our routine in 2006-2007, 
LocaLisa 3D navigation system was used in all patients. In group I, this allowed 
creating a smooth anatomical line without gaps, and in group II the system helped us to 
navigate the catheter back to any previous ablation spots. 
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Figure 3 Typical counter-clockwise atrial flutter in a patient undergoing a three-
application MVGT isthmus ablation  
Figure contains three surface electrograms, electrograms from a multipolar right atrial 
catheter and electrograms of an octopolar coronary sinus catheter. The mapping catheter 
is placed on the isthmus. (a) First ablation spot with rather large atrial bipolar signal. (b) 
Second RF application, results in immediate decrease of the local signal amplitude and 
fast termination of the flutter (c) As coronary sinus pacing showed no bidirectional 
block a third application was done resulting in isthmus block 
 
The procedures were performed during a fasting state, using local anaesthesia. A 20-
pole catheter was advanced to the right atrium, and positioned around the tricuspid 
annulus. An octopolar catheter was positioned in the coronary sinus and a quadripolar 
catheter in the right ventricular apex. All patients received full anticoagulation during 
the ablation procedure (heparine 100 IU/kg) following the local ablation protocol. An 8 
mm tip ablation catheter was used in all cases (Blazer, Boston Scientific). 
Radiofrequency energy was delivered for 60 s at each application point. Maximum 
power was set to 70 W, maximum temperature to 65°C in all patients regardless 
whether they were randomized to groups I or II. Procedural success was determined as 
the termination of the atrial flutter and achievement of a bidirectional CTI block. 
The primary endpoints of the study were procedure time, fluoroscopy time, 
radiofrequency application numbers, and total radiofrequency time. For group II the 
maximum bipolar atrial signal was determined as target. For group I, after the ablation 
procedure atrial bipolar signal amplitudes were measured off line at all ablation spots. 
Follow-up visits were scheduled at 3 and 6 months after the ablation procedure. 
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3.3. Defibrillation coil retention during orthotopic heart transplantation 
We conducted a single-centre, retrospective study, and reviewed all the medical and 
surgical reports of 117 patients who underwent HTX in the Erasmus MC in Rotterdam, 
between March 2005 and May 2011.  We further analyzed data of those 84 patients 
(72%) who had an ICD (n=53) or CRT-D implantation (n=31) prior to HTX. We 
determined the time from ICD implantation to HTX, the duration of the transplant 
procedure, the type and manufacturer of defibrillation leads, and the defibrillator lead-
related adverse events (AEs).  AEs were defined as lead fragment retention, lead 
perforation of cardiac chambers, evidence of conductor fracture on X-ray or as a sudden 
impedance rise, insulation failure, and macro-dislodgement of the lead.  All patients 
were closely followed after HTX as a routine part of their clinical management. No 
patient was lost to follow-up. 
 
3.4. Cardiac resynchronisation in chronic renal failure 
Clinical and echocardiographic data of 60 consecutive patients who underwent CRT-P 
or CRT-D implantation for primary or secondary prophylaxis of sudden cardiac death 
were analysed in this retrospective study. Implantations were done between May 2005 
and October 2006 in the Hungarian Institute of Cardiology.  
 We assumed the existence of chronic renal failure if serum creatinine 
concentration was >130 µmol/L on at least two separate days. Patients with both 
ischemic and non-ischemic dilated cardiomyopathy were included. The aetiology was 
considered ischemic when an old myocardial infarction was present, and/or any 
revascularisation procedure had been carried out before CRT. Patients ineligible of 
revascularisation were also included into the ischemic group.  
 Patient selection for CRT-P or CRT-D implantation had been performed 
according to the ACC/AHA/NASPE guidelines in operation at the time of implantation 
(Gregoratos G et al. 2002). Patients received optimal pharmacological therapy of 
chronic HF before selection to CRT. 
 The following baseline characteristics were recorded: age, gender, NYHA 
functional class, history of ischemic cardiomyopathy, diabetes, CRF, anaemia, atrial 
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fibrillation, presence of a permanent pacemaker, proportion of CRT-D at implantation, 
annual hospitalisation rate prior to implantation, and left ventricular ejection fraction. 
LVEF was calculated from the apical window of 2D-mode echocardiography using the 
modified Simpson’s rule. Available hospital records and outpatient follow-up 
documents were reviewed.  
 Data on change in NYHA functional class and change in LVEF were collected at 
a mean post-implantation period of 9.6 ±3.0 months. Improvement of one or more 
NYHA class was considered as a positive response to CRT. Data on all-cause mortality 
and the annual number of postoperative hospitalisations due to HF had been collected 
for 36 months. Seven patients were lost to follow-up, so 53 completed the whole course 
of the study. 
3.5.  Statistical methods 
3.5.1. Instantaneous rate-control of rapid atrial fibrillation with coupled and 
paired ventricular pacing 
Continuous data are shown as mean value±SD (or range); categorical data are expressed 
in absolute numbers and percentages. Continuous variables with normal distribution 
were compared using the paired t-test (changes in MPR due to CP or PP stimulation) 
and the unpaired t-test (comparison between MPR results of CP and PP). Analysis was 
performed using the statistical program R version 2.3.1 [R Development Core Team 
(2006), Foundation for Statistical Computing]. All tests were two-tailed and a P value of 
<0.05 was considered statistically significant. 
3.5.2. Maximum voltage-guided technique for cavotricuspid isthmus ablation 
during ongoing atrial flutter 
Values were expressed as mean±SD. Independent samples t-test for parametric and 
Kologmorov–Smirnov test for nonparametric data was performed to compare data. A p 
value <0,05 was considered to be statistically significant. 
3.5.3. Defibrillation coil retention during orthotopic heart transplantation 
Continuous variables were expressed as mean ± SD, categorical variables as absolute 
numbers and their percentages. Variables were compared by using a Fisher’s exact test 
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(gender, ischemic aetiology, device type), or using a Mann-Whitney test (patient age, 
lead age, HTX duration). All tests were two-tailed and a p value of <0.05 was reported 
as statistically significant. Analysis was performed using the statistical program SPSS 
PASW 17.0.2 (SPSS Inc., Chicago, 2009). 
3.5.4. Cardiac resynchronisation in chronic renal failure 
All continuous variables are expressed as mean±SD, non-continuous are as numbers and 
percentages.  Differences in baseline characteristics and in follow-up data between 
separate patient groups were compared using the unpaired Student t-test for continuous 
and a chi-square test for dichotomous variables, as well as a Mann-Whitney U-test for 
NYHA classes. Comparison between identical groups to assess the effects of CRT was 
performed using the paired Student t-test (continuous), chi-square test (dichotomous), 
and a Wilcoxon signed-rank test (NYHA classification). After completion of the three-
year long follow-up period, data on mortality were assessed using the Kaplan-Meier 
method. Comparison of cumulative survival rates was done using the log-rank test. 
Univariate Cox regression analysis was performed to calculate crude hazard ratios and 
their respective 95% confidence intervals on mortality with the following baseline 
variables: age, sex, device type, diabetes, CRF, anaemia, atrial fibrillation, ischemic 
cardiomyopathy, NYHA class, LVEF, prior pacing, and number of annual 
hospitalisations pre-implantation. All p values were two-tailed, and a p value of < 0.05 
was considered statistically significant for all tests. Analysis was performed with 
STATISTICA (version 8.0, StatSoft Inc, Tulsa, Oklahoma, USA). 
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4. Results 
4.1. Instantaneous rate-control of rapid atrial fibrillation with coupled 
and paired ventricular pacing 
 
Baseline patient characteristics 
The study population consisted of 16 predominantly male (75%) patients with a mean 
age of 56 years (range 44–70). Demographic and clinical data are shown in Table 1. The 
mean right ventricular ERP was 222±10.5 ms before CP and 214±10.9 ms before PP. 
 
Table 1 Baseline characteristics of patients 
 
Total number of patients 16 
Age in years (range) 56 (44-70) 
Males 12 (75%) 
Paroxysmal atrial fibrillation 11 (69%) 
Persistent atrial fibrillation 5 (31%) 
Diabetes 2 (12%) 
Hypertension 4 (24%) 
Dilated cardiomyopathy 
Previous myocardial infarction 
1 (6%) 
3 (18%) 
Mechanical pulse rate 113±9 
 
 
Results with the coupled pacing protocol 
Successful MPR control was achieved in all patients using CP. The MPR significantly 
decreased from baseline (113±9 vs. 58±4/min; P < 0.001) (Figure 4). The controlled 
rhythm remained irregular, as the pulse CL ranged between 896±24 and 1452±67 ms, 
and the index of irregularity at baseline and during CP was 0.43 and 0.38, respectively. 
Neither PVCs nor ventricular tachycardia occurred during CP.  
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Figure 4 The rate controlling effect of CP and PP at different drive trains 
CP resulted in a significant reduction of the mean MPR. During PP all drive trains 
resulted in significantly lower pulse rates compared to baseline, and the lowest MPR 
was achieved at a ventricular drive train of 700 ms. Abbreviations:  AF: baseline pulse 
rate during atrial fibrillation, rpm: rate per minute, Drive: drive trains with respective 
cycle lengths 
 
Results with the paired pacing protocol 
With different drive trains PP resulted in different regular MPRs (range 64±6 –
88±4/min). Increasing the drive train by 50 ms resulted in significantly lower MPR 
values as compared with the baseline (Figure 4). The lowest MPR achieved was found 
at the 700 ms drive train. With drive trains > 700 ms an increase in MPR was observed 
due to the occurrence of intercalated, spontaneously conducted atrial fibrillation beats. 
Continuous MPR control was only achieved in seven patients, while PP caused 
premature beats in nine patients (56%) [mean 7 (range 1–72) PVCs per patient], 
resulting in failure of continuous MPR control (Figure 5). In these patients PP was 
regarded unsuccessful. No ventricular tachycardia was observed during PP. 
 
There was no significant difference between the ERP of PP and CP protocols. Both CP 
and PP significantly reduced the MPR as compared to baseline (Figure 4). The lowest 
MPR achieved by PP was significantly higher than in the CP group  
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(64±6 vs. 58±4 /min; p<0.05). Neither death nor any life-threatening complication 
occurred during the study. 
 
 
 
Figure 5 Unsuccessful PP due to frequent PVC’s 
Frequent pacing-related PVC’s making the PP ineffective at a drive train of 600 ms. 
Pulse cycle lengths vary considerably (864 ms and 1680 ms). HRA electrode shows 
ongoing atrial fibrillation. Registration speed: 100 mm/sec 
Abbreviations: 
I, II, V1: surface ECG recordings; HRA p (sense): intracardiac recordings from high 
right atrium; RVA p (sense): pace/sense channel from the intracardiac electrode in the 
right ventricular apex; RVA d: distal electrode channel from right ventricular apex; 
ABP: radial arterial pressure curve; S1: marker of pacing extrastimuli 
 
4.2. Maximum voltage-guided technique for cavotricuspid isthmus 
ablation during ongoing atrial flutter 
 
Ablation data are shown in Table 2. In all primary and secondary endpoints the MVGT 
was superior to the anatomical approach. In all patients, atrial flutter was terminated 
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during ablation. However, this termination resulted in complete block in only 45% of 
the patients. In this regard there was no difference between group I and group II (42 vs. 
48%, respectively). At the conclusion of the ablation procedures bidirectional isthmus 
block was achieved in all cases. Procedure time was shorter in group II. Significantly 
less fluoroscopy was used in group II, less application needed for complete bidirectional 
isthmus block, and radiofrequency application duration was also shorter in group II. 
There were no major complications related to the procedures. Minor complications such 
as groin haematoma were not different between the groups. 
 
Mapping data 
Atrial bipolar signal amplitudes of each ablation sites were assessed. There was no 
difference between the maximum atrial bipolar amplitudes in groups I and II. This also 
refers to the identical baseline conditions of the two groups. 
 
Table 2 Baseline characteristics and results of flutter patients treated with the MVG 
method or with conventional linear anatomical ablation 
 
RF: radiofrequency 
 Group I (anatomical line) Group II (MVG) p 
Age (years)  60.6 58.7 NS 
Gender (F/M) 3/7 2/8 NS 
Procedure time (min) 107±40 47±6,2 0.01 
Fluoroscopy time (min) 22.6±10.6 12.1±3.8 0.01 
RF ablation numbers  27.1±21.5 5.9±2.4 0.001 
RF time (sec) 1370±1120 375±180 0.001 
Mapping amplitude (mV) 1.76±0.61 1.82±0.58 NS 
 
 
Follow-up data 
During the median follow-up of 8.4±2.4 months, 1–1 recurrences of atrial flutter were 
detected in each group and redo procedures were performed successfully (not included 
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into the ablation results). The occurrence of atrial fibrillation was not statistically 
different between the groups (group I 25% vs. group II 34%).  
 
4.3. Defibrillation coil retention during orthotopic heart transplantation 
The study population consisted of 84 predominantly male (54 cases), end-stage heart 
failure patients aged 46.4 ± 9.9 years, who had a previously implanted primary 
prevention ICD system. Ischemic cardiomyopathy was the cause of heart failure in 43% 
of the cases. The distribution of the implanted devices was: single-chamber ICD (SC-
ICD) in 26 patients (31%), dual-chamber ICD (DC-ICD) in 26 (31%), and a CRT-D in 
32 (38%). The implanted defibrillation lead configuration was single-coil in 33 patients 
(39%) and dual-coil in 51 (61%). The following defibrillation lead manufacturers were 
represented: Biotronik 10 leads (12%), Guidant (and former CPI) 19 leads (22%), 
Medtronic 25 leads (30%), and St Jude Medical 30 leads (36%).  The mean time from 
defibrillation lead implantation to transplantation was 36 ± 30 months. Baseline 
characteristics of the ICD patients grouped by lead configuration are shown in Table 3.  
Patients in the single-coil group were younger, but other variables as gender, ischemic 
aetiology, duration of HTX procedure, and lead age did not differ significantly.  
 
Table 3 Baseline characteristics of patients grouped by the configuration of 
defibrillation lead 
Abbreviations: HTX heart transplantation, SC-ICD: single-chanber ICD 
DC-ICD: dual-chamber ICD, CRT-D: biventricular ICD 
 Single-coil 
(n=33) 
Dual-coil 
(n = 51) 
p 
Age (y) 42±11 49±8 0.01 
Female 13 (39%) 16 (31%) ns 
Ischemic aetiology  14 (42%) 22 (43%) ns 
Lead age (mo) 31±25 39±33 ns 
HTX duration (min) 450±96 451±102 ns 
Device type 
       SC-ICD 
       DC-ICD 
       CRT-D 
 
8 (24%) 
12 (37%) 
13 (39%) 
 
18 (35%) 
14 (28%) 
19 (37%) 
ns 
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No lead-related AEs occurred in the single-coil group, while a total of eleven (22%) 
ICD lead-related AEs were documented in the dual-coil group immediately after HTX. 
All of the AEs were retained proximal coil fragments of ICD leads. No other kind of 
defibrillator lead problems occurred post-transplantation. Additionally, a retained atrial 
lead fragment (CPI 4244 model) causing no further complications at 5 months follow-
up is of note in the dual-coil group. Characteristics of the dual-coil cohort grouped by 
the presence or absence of fragment retention are displayed in Table 4. The type of 
implanted device has reached marginal significance (p=0.04) as only SC-ICDs and 
CRT-D devices, but no DC-ICDs were represented in the retained coil group. 
 
Table 4 Characteristics of patients with dual-coil defibrillator leads 
 
Abbreviations: HTX heart transplantation, SC-ICD: single-chanber ICD 
DC-ICD: dual-chamber ICD, CRT-D: biventricular ICD 
 Retention 
(n = 11) 
No retention 
(n = 40) 
p  
Age (y) 52±7 48±8 ns 
Female 4 (36%) 12 (30%) ns 
Ischemic aetiology  2 (18%) 20 (50%) ns 
Lead age (mo) 40±35 39±33 ns 
HTX duration (min) 443±93 454±105 ns 
Device type 
       SC-ICD 
       DC-ICD 
       CRT-D 
 
6 (54%) 
0 
5 (46%) 
 
12 (30%) 
14 (35%) 
14 (35%) 
0.043 
 
 
 
Details and outcome of the patients who were affected by fragment retention are listed 
in Table 5. Nine different heart surgeons were involved in the HTX procedures, all with 
ample clinical experience in this field. There was no difference in the distribution of 
surgeons according to the presence or absence of lead retention. The proportion of 
manufacturers in the dual-coil group was: St Jude Medical 41%, Medtronic 26%, 
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Guidant 23%, and Biotronik 10%. There was no fragment retention among the 
Biotronik leads in our patients. The fragmented defibrillation leads came from the St. 
Jude Medical Riata family in the majority of cases (7/11 = 64%, 43% of all St Jude 
Medical dual-coil leads); whereas the Medtronic Sprint (2/11 = 18%, 20% of all 
Medtronic dual-coil leads) and CPI-Guidant families (2/11 = 18%, 22% of all Guidant 
dual-coil leads) were represented in the other four cases (Table 5). Except three patients, 
the ICD extraction procedures of those eleven transplantations were considered 
complete removals at the time of the transplant procedure, and in eight cases only the 
postoperative chest X-ray or CT-scan revealed the retained proximal defibrillation coil 
fragments in the body (Figure 6).  On follow-up, one coil fragment migrated into the 
pericardial space, another into the right atrium causing perforation of the interatrial 
septum. The latter patient died of multi-organ failure 3 months after HTX. One patient 
underwent rethoracotomy due to a S. aureus-related purulent mediastinitis and cardiac 
tamponade, and he also developed right jugular and right femoral venous thrombosis, 
but finally he has recovered.  
Four patients died in the retention group, their cause of death is reported in Table 5. Of 
the 40 patients without retention in the dual-coil group, and of the 33 patients in the 
single-coil group also four-four patients died, but the small numbers and absence of any 
relation of the deaths to the retained fragments makes any comparison meaningless. In 
two patients an uncomplicated percutaneous transvenous lead fragment extraction was 
performed using the femoral route 19 and 56 days after transplantation. In the rest of the 
patients including the one with the coil in the pericardium, our clinical decision was to 
leave the fragments in place after individually weighing the inherently elevated risks 
against the potential benefits of a removal procedure.
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Table 5 Baseline data and characteristics of patients with defibrillation lead-related complications 
CRT-D: biventricular ICD, DVT: deep vein thrombosis, HTX: heart transplantation, RV: right ventricular, SC-ICD: single chamber ICD 
†: not related to the retained fragment, ‡: thrombosis in right femoral and right jugular veins, left-sided implantation 
Patient 
number 
Gender Age at 
implant 
Aetiology Lead 
manufacturer 
Device 
type 
Defibrillation 
lead type 
Lead age at 
HTX 
(months) 
post-HTX 
follow-up 
(months) 
Outcome 
1 Female 50 Non-
ischemic 
Medtronic CRT-D Sprint Fidelis 
6949 
11 0 died, primary 
graft failure 
2 Male 63 Non-
ischemic 
St Jude 
Medical 
SC-ICD Riata 1580 15 5 died, sepsis 
3 Male 50 Non-
ischemic 
St Jude 
Medical 
SC-ICD Riata 1580 16 49 alive, fragment 
extracted 
4 Female 39 Non-
ischemic 
St Jude 
Medical 
SC-ICD Riata 1580 18 48 alive, fragment 
extracted 
5 Male 50 Ischemic St Jude 
Medical 
SC-ICD Riata 1580 4 48 alive, no 
complications 
7 Male 54 Non-
ischemic 
St Jude 
Medical 
SC-ICD Riata 1580 52 3 died, multi-
organ failure † 
8 Female 50 Non-
ischemic 
Medtronic CRT-D Sprint Quattro 
6947 
68 12 alive, no 
complications 
9 Female 53 Non-
ischemic 
St Jude 
Medical 
SC-ICD Riata 1570 50 0 died, graft RV 
failure 
10 Male 56 Non-
ischemic 
St Jude 
Medical 
CRT-D Riata 7001 48 2 alive, DVT 
mediastinitis ‡ 
11 Male 62 Non-
ischemic 
Guidant CRT-D Endotak 0155 37 62 alive, no 
complications 
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Figure 6  Chest X-rays of a retained coil fragment  
A dual-coil defibrillation lead and a defibrillator before HTX (A), the situation after 
HTX with the retained coil fragment in the superior caval and innominate vein (B), and 
following removal of the retained proximal shock coil (C). The lead was cut through the 
proximal coil during HTX 
 
4.4. Cardiac resynchronisation in chronic renal failure 
The age of the total study population was 58.1±11.7 years (range: 19-79), women were 
represented in 22% (Table 6). Twenty-two patients (37%) suffered from chronic renal 
failure, 24 (40%) had diabetes, and 10 patients (17%) were anaemic. Advanced heart 
failure was marked by a mean baseline NYHA class of 2.8±0.6 and a poor LVEF 
(25.4±6.2%). The annual number of hospitalisations due to HF was 2.4±1.9 pre-
implantation. The worse clinical condition of the CRF group was marked by the 
advanced NYHA class (3.1±0.5 vs. 2.6±0.6 p=0.01), more hospitalisations (3.4±2.4 vs. 
1.7±1.1 p=0.005), and a previous need for more conventional pacemaker implantations 
(27 vs. 5% p=0.015). Significantly more patients received a CRT-D device in the CRF 
group (73 vs. 45% p=0.035). 
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Table 6 Baseline characteristics of CRT recipients 
 
CRF: chronic renal failure, CRT-D: cardiac resynchronisation therapy with defibrillator, 
Hgb: haemoglobin, AF: atrial fibrillation, NYHA: New York Heart Association, 
LVEF: left ventricular ejection fraction 
 
 
Follow-up results 
CRT resulted in significant clinical improvement in both groups in terms of reduction of 
NYHA class and in reduction of the annual number of hospitalisations (Table 7). 
Although there was a tendency towards an improvement in LVEF, this variable did not 
reach significance. 
The overall clinical response rate of the whole population to CRT after 9.6±3.0 months 
was 76%, and 63 % vs. 84% in CRF vs. non-CRF patients, respectively. The effect of 
CRT on the response rate, on the change of NYHA class, on the improvement in LVEF 
and on the annual rate of hospitalisations did not differ significantly among the groups 
with or without CRF (delta column in Table 7).  
 total  CRF non-CRF P 
age 58.1±11.7 62.1±12.0 55.8±11.1 <0.05 
female 13 (22%) 2 (9%) 11 (29%) NS 
CRT-D  33 (55%) 16 (73%) 17 (45%) <0.05 
ischemic  cardiomyopathy 30 (50%) 15 (68%) 15 (39%) <0.05 
diabetes  24 (40%) 14 (64%) 10 (26%) <0.05 
chronic renal failure  22 (37%)    
anaemia (Hgb<110 g/L) 10 (17%) 8 (36%) 2 (5%) <0.05 
persistent/permanent AF  13 (22%) 4 (18%) 9 (24%) NS 
prior pacing  8 (13%) 6 (27%) 2 (5%) <0.05 
hospitalisation pre-implantation 2.4±1.9 3.4±2.4 1.7±1.1 <0.05 
NYHA functional class 2.8±0.6 3.1±0.5 2.6±0.6 <0.05 
LVEF (%) 25.4±6.2 27.4±4.4 25.9±7.1 NS 
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Table 7 Follow-up results of patients suffering from CRF and their controls 
 
For abbreviations see footnote of Table 6 above 
  CRF    non-CRF   delta 
 preimpl postimpl P  preimpl postimpl P P 
hospitalisations 3.4±2.4 0.9±1.1 <0.01  1.7±1.1 0.4±0.8 <0.01 NS 
NYHA 3.1±0.5 2.3±0.8 <0.01  2.6±0.6 1.8±0.6 <0.01 NS 
LVEF % 24.7±4.4 26.1±4.0   NS  25.9±7.1 29.2±7.4  NS NS 
responder       - 14 (64%     -      - 32 (84%)   - NS 
 
 
Mortality 
During the 36-month long follow-up period seven patients were lost to follow-up, all of 
them were dropped out after the initial six months of the study. Among the remaining 
53 patients 18 deaths occurred, resulting in an all-cause mortality rate of 34%. The ratio 
of CRT-P/CRT-D was 1:1 among the deceased. Thirteen patients died due to end-stage 
HF, two died due to ventricular fibrillation resistant to multiple ICD therapy, one died 
in lung cancer, one in acute renal failure, and we lost one patient in multi-organ failure 
of septic origin 12 months after CRT-D implantation. There were no procedure related 
deaths.  
According to the Kaplan-Meier tests for survival, all-cause mortality was significantly 
higher in CRF patients (61 vs. 17% p<0.01). (Figure 7) 
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Figure 7 Kaplan-Meier survival function curves of patients suffering from chronic 
renal failure over the three-year long follow- up period 
Patients with normal renal function had a significantly better survival over the 3-
year long follow-up period 
P value represents log-rank test result.  CRF: patients with chronic renal failure, no-
CRF: patients with normal renal function 
 
 
Mortality data were also compared on the basis of the type of device implanted (CRT-P 
or CRT-D). The survival of CRT-D patients showed a clearly significant difference in 
favour of patients with normal renal function. When comparing the presence or absence 
of a defibrillator (i.e. CRT-D), the survival curves of CRF patients run along a similar 
course without any significant difference (Figure 8). Univariate analysis revealed that 
the presence of atrial fibrillation, CRF, and the number of preoperative hospitalisations 
proved to be as significant crude predictors of death (Table 8).  
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Figure 8 Kaplan-Meier survival function curves of CRT patients with and without 
chronic renal failure with regard to the presence or absence of ICD 
 
The difference in survival of CRT-D patients with or without CRF was clearly 
significant, favouring patients with normal renal function.  
P represents log-rank test result between CRT-P and CRT-D patients suffering from 
CRF 
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Table 8 Univariate analysis of the crude predictors of excess mortality in CRF group 
 
HR: hazard ratio, CI confidence interval, CRF: chronic renal failure, prehosp#: annual 
number of hospitalisations before implantation 
 HR 95% CI P 
atrial 
fibrillation 2.85 1.07-7.43 0.033 
CRF 5.30 1.94-14.4 0.001 
anaemia 4.58 1.58-13.2 0.004 
prehosp# 1.55 1.27-1.88 0.001 
 
 
 
In this observational study of CRT patients with chronic renal failure our main findings 
were the following: 
CRF patients had a significantly worse baseline clinical state before implantation in 
terms of other comorbidities, previous hospitalisations, and NYHA functional class. 
CRT resulted in a significant reduction of the number of postoperative hospitalisations 
and a reduction in NYHA class in both subgroups regardless of the presence or absence 
of CRF.  
Chronic renal failure conferred a significantly higher all-cause mortality rate over a 
long-term follow-up period despite the significantly higher defibrillator implantation 
rate in this group.  
Predictors of higher mortality were the presence of atrial fibrillation, CRF, anaemia, and 
the higher number of annual hospitalisations pre-implantation. 
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5. Discussion 
5.1. Instantaneous rate-control of rapid atrial fibrillation with coupled 
and paired ventricular pacing 
 
This study demonstrates the feasibility of CP and PP to control MPR during atrial 
fibrillation. The main finding is that CP results in effective pulse control, while PP is 
also effective in reducing the heart rate in some patients, but causes frequent PVCs in 
half of the cases, resulting in failure of continuous MPR control. Although a reduced 
and modulated heart rate can be achieved by PP, this form of MPR control also raises 
safety issues as it can be rather arrhythmogenic. It is unlikely that the observed 
differences and the higher arrhythmogenicity in the PP group would have been the 
result of the slight, insignificant differences in baseline ERPs. The optimal heart rate 
during atrial fibrillation is still in question. Although the RACE II trial (Van Gelder IC 
et al. 2010) has concluded that lenient rate control (resting heart rate 110–80/min) is not 
inferior to strict control, this study included only patients with permanent atrial 
fibrillation unlike our study, where paroxysmal and persistent atrial fibrillation patients 
were represented, whose mean resting heart rate was 113/min. 
 
5.1.1. Rationale of coupled and paired pacing and energetic considerations 
 
Previous work of Lau et al. conducted in 1990 in humans showed that a timing of  
approximately 20 ms above the ERP proved to be the best CI for CP. Increasing this 
interval up to 50 ms did not significantly affect the detected peripheral pulse rate or the 
effectiveness of coupling, while shortening the CI significantly affected both 
parameters. Although paired stimulation enhances contractility by postextrasystolic 
potentiation, it greatly increases oxygen consumption. The lack of dramatic changes in 
myocardial metabolism resulting from CP was observed by Yamada and colleagues. In 
their experiments CP only non-significantly increased myocardial oxygen consumption, 
while it increased cardiac work mainly by improving cardiac efficiency (Yamada H et 
al. 2004, Yamada H et al. 2006).  Moreover, myocardial lactate extraction as an 
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indicator of myocardial oxygen consumption was not affected by CP as showed by Lau 
et al. in 1990. During CP every paced QRS prevents the AV-conduction of an intrinsic 
beat, so the number of ventricular depolarisations is practically unchanged. Based on all 
these findings, one can speculate that the net effect of CP on cardiac energy expenditure 
might be neutral. We have demonstrated that PP has potential arrhythmogenic effects, 
and this finding also emphasizes the inferiority of this pacing modality compared with 
CP. 
 
5.1.2. Alternative non-pharmacological methods to regulate or reduce the 
ventricular rate during atrial fibrillation 
 
Continuous pacing with the aid of the incorporated ventricular rate regularization 
algorithm in permanent pacemakers has the possibility to effectively regularize the heart 
rate and to enhance rate recovery after exercise during atrial fibrillation, but it has 
hardly any effect on reducing the pulse rate (Ciaramitaro G et al. 2006). There are other 
innovative methods to provide prompt non-pharmacological rate control in atrial 
fibrillation. Selective parasympathetic neurostimulation of the right inferior 
ganglionated plexus via an endocardial atrial electrode can result in abrupt slowing of 
the AV-conduction as it has been demonstrated in an experimental canine model by 
Mischke K et al. in 2010. They achieved a narrow-QRS, continuous, effective, and 
adjustable rate control of permanent atrial fibrillation for years without reported 
proarrhythmia. They also implanted a conventional atrial and a back-up ventricular lead, 
so there were three intravascular leads altogether. A human case report with successful 
temporary high-frequency endocardial vagal stimulation in the ostium of the coronary 
sinus with an external 50 Hz stimulator was published by Bianchi S et al. in 2009. This 
patient had permanent atrial fibrillation with uncontrollable ventricular rates and NYHA 
IV class decompensated heart failure prior to treatment. Admitting that cardiac 
ganglionar neurostimulation is a promising technique, the most important theoretical 
advantage of CP over this method is that it does not require placement of an additional 
lead in a delicately selected atrial position. 
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5.1.3. Future clinical implications 
 
Our findings suggest that CP should be reconsidered as a pacing therapy during atrial 
fibrillation, and it might have a potential role in future clinical use. Rapid paroxysmal 
atrial fibrillation is not a rare phenomenon especially in a post-operative period after 
cardiac surgery, or in the intensive care, or coronary care unit and it is often associated 
with poor ventricular function. The potential advantages of CP compared with drugs 
slowing the heart rate include the rapid onset of action and the absence of negative 
inotropic effects. As patients frequently have temporary cardiac pacemaker systems in 
the early post-operative stage, or in the intensive care unit due to critical bradycardia, 
the use of a CP algorithm might be a practical and useful strategy to slow down the 
MPR, and to improve peripheral circulation. Regarding those patients living with 
permanent ICDs or CRT-D devices, delivery of CP therapy might be a method to 
promptly control their pulse rate during rapid transient atrial tachyarrhythmias even 
before they seek medical attention. Slowing of the pulse rate could prevent arrhythmia-
related heart failure events and tachycardia induced cardiomyopathy, and could serve as 
a bridge to hospitalisation. This optional CP feature could be triggered by the mode-
switch of the device, or after matching the criteria of an atrial fibrillation discrimination 
algorithm. Although no arrhythmogenic effect of CP was found in our short-term study, 
to minimize the risk of this ventricular pacing protocol, such a therapy should be 
reserved for patients living with ICD. Physiological and pathological factors, as well as 
medications can alter the ventricular ERP, so frequent determination of the ERP and 
readjustment of the CI will be important in order to provide effective therapy. This 
would also avoid pacing in the vulnerable period when the ERP lengthens. As our 
observations are based on an acute study, we clearly need more data from a future 
clinical study addressing the question of effectiveness, proarrhythmia, and the frequency 
of CI readjustments over days or some weeks. We emphasize that this pacing method is 
most likely useful for temporary therapy and in case of frequent induced proarrhythmia 
it should be stopped. Theoretically the V-pace ratio would be 50% during CP, high 
enough to raise concerns in heart failure patients with ICD leads in right ventricular 
apical position. Noteworthy, in the further analysis of the DAVID trial (Sharma AD et 
al. 2005) and in the MOST sub-study (Sweeney MO et al. 2003) the deleterious effects 
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of frequent (>40%) chronic right ventricular pacing became manifest over long months, 
but CP therapy is intended only for temporary use (days to weeks) in transient 
tachyarrhythmias, and not for long-term pacing.  
Future clinical investigations should address long-term safety and efficacy issues, as the 
control of rapid post-operative atrial fibrillation episodes with imminent acute heart 
failure after cardiac surgery. If these studies provide positive results, development of a 
CP algorithm in permanent ICD or CRT-D devices might be a reasonable next step. 
 
 
5.2. Maximum voltage-guided technique for cavotricuspid isthmus 
ablation during ongoing atrial flutter 
The MVGT technique is an effective method in decreasing procedure time and the 
number of RF applications needed for bidirectional cavotricuspid isthmus block. We 
were the first to point it out that this ablation method is also applicable during ongoing 
atrial flutter and our results are in favour of this technique over the conventional one.  
 
5.2.1. Former results with the MVGT and implications for clinical routine 
 
The above mentioned anatomical observations serve as a rationale for the development 
of this alternative approach. So far a few publications demonstrated the effectiveness of 
MVGT (Redfearn DP et al. 2006, Subbiah RN et al. 2007, Posan E et al. 2007, Lewalter 
T et al. 2012). In most of these studies ablation was performed during sinus rhythm or 
during atrial pacing. A retrospective analysis (Subbiah et al. 2007) suggests that indeed 
sinus rhythm is an independent factor predicting successful ablation using MVGT. 
Contrary to this, our study clearly demonstrates that the technique is feasible during 
ongoing arrhythmia. We strongly believe that this is important because unnecessary 
cardioversions before ablation with their potential complications can be avoided. 
Moreover, in this study the bipolar atrial signal amplitudes recorded with the 8 mm tip 
ablation catheter (1.76 mV) were very comparable with the amplitudes presented in 
former publications (Redfearn DP et al. 2006, Subbiah RN et al. 2007, Posan E et al. 
2007). 
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During the follow-up of this study we did not observe differences in the recurrence rates 
in atrial flutter. The occurrence of other arrhythmias as atrial fibrillation was also not 
statistically different. Another key issue is indeed, when a quicker method is introduced 
into clinical practice whether it is not compromising long-term results. Unfortunately, 
this study was limited by the low number of patients and was powered only to assess 
short term outcome, therefore long-term efficacy still remains a question and requires 
further investigation. During our 6-month follow-up period there was no statistically 
significant difference between flutter recurrence rates. Furthermore, some additional 
data are available regarding the follow-up of these patients from the group who 
developed the technique. It seems that in a much larger group of 76 patients undergoing 
the same technique, during a mean follow-up of 18 months there was no higher rate of 
recurrence observed (Subbiah RN et al. 2007). This was also seen in a study where 
bidirectional block was achieved just with a single radiofrequency shot (Posan E et al. 
2007). 
 
5.2.2. Clinical impact of the results 
 
One of the most important achievements using this technique is shortening of procedure 
time. This becomes even more important when CTI ablation is performed as part of a 
more extensive ablation procedure for atrial fibrillation. In these cases shortening of 
procedure time is quite important and decreases patient burden as well. This would 
especially apply for patients suffering from heart failure, who can hardly tolerate long 
ablation sessions while lying supine on the table. Furthermore, novel energy sources are 
being investigated for transcatheter ablation. Cryoenergy has some significant safety 
advantages but these are counterbalanced by the significantly longer procedure times. 
Moreover, studies suggest slightly worse procedural outcome using cryothermy for CTI 
ablation (Montenero AS et al. 2005, Marrouche NF et al. 2003). This latter together 
with a longer procedure times makes cryothermy impractical for such indication.  
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5.3. Defibrillation coil retention during orthotopic heart transplantation 
Our data suggest that disruption and incomplete removal of defibrillation coils at the 
time of heart transplantation is a clinically frequent and relevant problem, which 
affected 22% of our dual-coil lead cohort, but not the single-coil cohort. As different 
experienced surgeons performed the operations in these cases, any personal bias was 
unlikely. During the orthotopic HTX procedure the distal parts of all the leads, 
including the dual-coil defibrillation lead, are cut through at the atrial level and 
explanted together with the failed heart. The generator and the proximal parts of the 
leads are explanted through the generator pocket using manual simple traction technique 
(Magliato KE et al. 2001, Jordaens L et al. 1996) at the end of the HTX procedure 
where fluoroscopy is not available in the theatre. The complications are highly 
suggestive of a specific, lead design related problem.  We could only address here the 
specific lead design problem of the St Jude Riata 1580 defibrillation lead, as the 
problems with the other lead types remain to be elucidated. The St Jude Medical Riata 
defibrillation lead family, which is no longer merchandized, includes over 20 individual 
models. The Riata 1580 dual-coil defibrillation lead is used to be manufactured 
differently than other dual-coil leads (Porterfield JG et al. 2009). In this lead the 
proximal end of the proximal coil is not welded to the conductor, only the distal end of 
the proximal coil has electrical connection and firm fixation to the conductor by 
welding. When the coil is cut through and the lead is under traction from the pocket, the 
defibrillation coil itself can stay in place fibrously affixed to the vasculature while the 
conductor can easily slide out of it (Figure 9), since the coil was cut above the welding. 
Based on these observations we strongly suggest that intersection of the ICD lead 
should not be done through the coil, the lead should be cut through between the two 
coils, instead (Figure 10). This would prevent the retention of coil remnants in the 
venous system.  
Although the Riata defibrillator lead family is no longer available in the market, the 
topic is still important because there are still a considerable number of patients living 
with implanted Riata shock leads, and some of them will definitely become a candidate 
for HTX. Patients with dual-coil defibrillation leads need extra awareness from the 
surgeon during HTX and lead explantation, as the ICD lead must be cut between the 
coils and never through the proximal coil. All explanted materials should be thoroughly 
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checked for completeness. The importance of removal of all the abandoned hardware at 
the time of cardiac transplantation is obvious, as the risk of infection is high during life-
long immunosuppressive therapy, and other complications as thrombosis and migration 
are also associated with retained foreign bodies. Preference of single-coil ICD systems 
is highly recommended in patients awaiting HTX. The post-hoc analysis of the 1820 
patients of the MADIT-CRT study revealed that the dual-coil cohort had a somewhat 
lower average defibrillation threshold (1.8 joules) at implantation, no any clinical- or 
survival advantage favouring dual-coil leads became obvious during  the 3 year-long 
follow-up period (Kutyifa V et al. 2013). 
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Figure 9 Detachment of the shock coil 
Proximal part of the proximal shock coil of a demo St Jude Medical Riata 1580 dual-
coil defibrillation lead in close-up. As the coil is not fixed firmly at its proximal 
junction to the conductor by welding, when it is cut through and the lead is under 
traction, the shock coil fragment can stay in place fibrously affixed to the vasculature 
while the conductor simply slides out of it. White arrow indicates the dislocation of the 
proximal coil from the junction. 
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Figure 10 View of an intact St Jude Medical Riata 1580 lead  
Area between green lines indicates the recommended point for intersection of the lead 
during heart transplantation. This must be done between the distal and proximal shock 
coils or more proximally from the proximal coil, and never through the coil itself (red 
cross). 
 
5.4. Cardiac resynchronisation in chronic renal failure 
 
5.4.1. Outcomes of CRT in renal failure 
 
Publications on the follow-up of CRT patients suffering from chronic renal failure 
mainly point to a significantly worse outcome. Delnoy and colleagues reported higher 
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mortality associated with renal dysfunction, male sex, elevated NT-proBNP and left 
atrial dilatation (Delnoy PP et al. 2007). Their work focused on reverse remodelling of 
130 CRT patients over 2 years. Shalaby et al. divided an unselected cohort of 330 CRT-
D recipients into tertiles by creatinine level (Shalaby et al. 2008). In their retrospective 
analysis, mortality rate was significantly higher in the highest tertile compared to all 
others, and an elevated baseline creatinine level significantly predicted all-cause 
mortality during a mean follow-up of 19.7 months. When creatinine level was 
investigated as a continuous variable, an increase by 0.1 mg/dL was associated with an 
increase of 11% in the risk of death. Fung et al. worked up data of 85 CRT patients 
retrospectively, and reported significantly higher all-cause mortality among patients 
whose renal function deteriorated after 3 months of implantation (Fung JW et al. 2007). 
They found a positive correlation between the change in LVEF and the change in 
glomerular filtration rate. Boerrigter et al. categorized the patients of the MIRACLE 
study into tertiles according to their estimated glomerular filtration rate (eGFR) 
(Boerrigter D et al. 2008). CRT improved LV function in all tertiles, whereas a slight 
but significant improvement in eGFR was seen only in the group with the lowest eGFR 
(<30 ml/min per 1.73 sqm) six months after implantation. This underlines the fact that a 
favourable haemodynamic response to CRT can improve renal function in patients with 
advanced renal failure. Unfortunately the authors did not investigate data on longer 
follow-up and mortality. Data of the COMPANION trial were analyzed by Saxon et al. 
for the predictors of sudden cardiac death. The risk correlated significantly with the 
presence of chronic renal insufficiency and NYHA IV functional class (Saxon LA et al. 
2006). In a large prospective study (n=542) conducted through six years by Bai et co-
workers, chronic renal failure, diabetes mellitus, and the history of atrial fibrillation 
proved to be as strong independent predictors of death after CRT implantation (Bai R et 
al. 2008).
 
 
5.4.2. Mortality of ICD recipients suffering from CRF 
 
There are convincing data in the literature on the unfavourable outcome of ICD patients 
suffering from renal insufficiency. Even the post-hoc analysis of MADIT-II revealed 
that renal failure increased the risk of all-cause mortality and arrhythmic death 
DOI:10.14753/SE.2015.1816
 52 
(Goldenberg I et al. 2006).
 
A recent meta-analysis carried out by Korantzopoulos et al. 
with data of 3010 patients has shown that CRF was associated with increased mortality 
(HR: 3.44) (Korantzopoulos et al. 2009).  
 
5.4.3. Utilisation of CRT-D over CRT-P could not reduce mortality in our CRF 
patients 
 
In our study 73% of the CRF patients received CRT-D, whereas in the group of patients 
with normal renal function this rate was only 45% (Table 6). This significant selection 
difference can be explained by the worse baseline clinical condition of CRF patients, 
which is mirrored by the higher incidence of life-threatening spontaneous or inducible 
arrhythmias prior to implantation. A selection bias could be a much smaller impact on 
this issue as the relationship between renal function and CRT outcomes had not been 
widely known by the time our patients received their devices. Despite the high rate of 
CRT-D use, our three-year long follow-up revealed that mortality was significantly 
higher in the cohort with renal failure (Figure 7). Unlike in ischemic cardiomyopathy, 
where a significant survival advantage of CRT-D over CRT-P was described by Kutyifa 
et al in their single-center retrospective study of 1122 patients over a 5 year-long 
follow-up period (Kutyifa V et al. 2014). It is of note, that there is no clear primary 
evidence of the superiority of CRT-D over CRT-P as no randomized trial with this 
particular primary goal has been designed and conducted yet. The current European 
guideline recommends both types of devices with similar level of evidence, and remarks 
that candidates for CRT-D should have a > 1 year reasonable survival time with good 
functional status (Brignole M et al. 2013). This guideline also gives some guidance to 
favour CRT-P in patients suffering from severe renal insufficiency or on dialysis. In our 
CRF cohort only more than half of the patients were alive after 12 months, and any 
survival advantage with a CRT-D system did not become apparent during the 3-year 
follow-up (Figure 8). 
A further large, prospective study with longer follow-up is needed to clarify the role of 
CRF on the survival of CRT-P/D patients and to adopt its results into the future 
guidelines to strengthen the evidence for the selection of the most appropriate device. 
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6. Conclusions 
6.1. Instantaneous rate-control of rapid atrial fibrillation with coupled 
and paired ventricular pacing 
 
1. We can conclude that both CP and PP promptly and feasibly reduce the pulse 
rate during rapidly conducting atrial fibrillation.  
2. PP has the advantage of achieving different target heart rates with different 
drive trains. 
3. We have demonstrated first that CP has a more pronounced and more 
effective rate-slowing effect.  
4. No life-threatening arrhythmia occurred during the study. CP seems to be less 
proarrhythmic regarding the number of triggered PVCs. 
 
6.2. Maximum voltage-guided technique for cavotricuspid isthmus 
ablation during ongoing atrial flutter 
 
1. Our results proved it first in literature that MVGT is a feasible method even 
during ongoing isthmus-dependent atrial flutter. Previous works showed similar 
results only during coronary sinus pacing, when the arrhythmia was not present 
at the time of the procedure. 
2. Our data confirm that MVGT is an effective technique to considerably 
decrease procedure, fluoroscopy, and radiofrequency application times making it 
an appealing technique for heart failure patients, as well. 
 
6.3. Defibrillation coil retention during orthotopic heart transplantation 
 
1. Our group was the first in demonstrating that defibrillation lead fragment 
retention is a clinically relevant problem during orthotopic HTX, as 22 % of 
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patients with dual-coil defibrillator lead shown retained fragments in the 
vasculature. 
2. The majority of cases came from the Riata shock lead family. 
3. No single-coil defibrillator lead removal resulted in fragment retention. 
4. In case of a retained lead fragment early removal should be considered. 
5. The use of single-coil defibrillation leads in candidates to HTX is highly 
recommended to prevent such complications. 
 
6.4. Cardiac resynchronisation in chronic renal failure 
 
1. Patients suffering from CRF have a positive short-term clinical response to 
CRT with improvement in NYHA functional class and a decrease in the number 
of hospitalizations, but their survival benefit is strongly questionable on the long 
run. 
2. In our study even the significantly higher CRT-D implantation rate in CRF 
patients could not abolish this unfavourable outcome.  
3. Predictors of an excess mortality were the presence of atrial fibrillation, 
anaemia, more hospitalizations pre-implantation, and the presence of CRF at 
baseline.  
 
 
 
 
My thesis just gave a brief overview of the rather immense field of arrhythmias in heart 
failure. This field is under extensive research nowadays, and the resolved questions just 
bring up new questions and new directions for future research. The main objective of 
my PhD work was to introduce a few new advances that I with my colleagues made and 
to put them into the context of contemporary non-pharmacological arrhythmia 
management. I hope that these small steps we made will also move forward our utmost 
goal: to better serve patients through mastering ourselves in anti-arrhythmic treatment. 
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7. Summary 
 
Development of chronic heart failure can trigger arrhythmias and vice versa. Non-
pharmacological treatment of tachyarrhythmias in systolic heart failure has a firm 
ground in the management of both supraventricular and ventricular rhythm 
disturbances. Ablative or device-based treatment of tachyarrhythmias not only improves 
quality of life but also can reverse systolic dysfunction and adverse left ventricular 
remodelling. We have demonstrated that both coupled and paired ventricular pacing can 
promptly and feasibly reduce the pulse rate during rapidly conducting atrial fibrillation, 
and coupled pacing seems to be less proarrhythmic. We were the first to point out the 
feasibility and efficacy of the maximum-voltage guided technique in cavo-tricuspid 
isthmus ablation during ongoing typical atrial flutter. This method significantly reduces 
procedure time, which is advantageous in patients suffering from heart failure. We have 
highlighted it first that the incomplete removal of dual-coil ICD shock leads during 
orthotopic heart transplantation is a significant problem, and this failure can be 
attributed to a special lead-design issue. Awareness of the mechanism of lead-retention 
in the venous system is essential during heart transplantation as abandoned fragments 
can potentially lead to serious consequences in immune suppressed patients. The use of 
single-coil defibrillation leads in candidates to heart transplantation is highly 
recommended. Co-morbid conditions of patients who are candidates for cardiac 
resynchronisation therapy can influence their survival fundamentally. Our retrospective 
study conducted in 2009 have demonstrated that chronic renal failure in CRT recipients 
confers extra mortality risk, and this risk cannot be counterbalanced by the more 
frequent utilisation of defibrillators (CRT-D) in this subgroup. Awareness of serious 
comorbidities now emphasized in the current 2013 edition of the European guideline of 
pacing and cardiac resynchronisation therapy, and this guideline recommends utilisation 
of CRT-P over primary preventional CRT-D in chronic renal failure.  
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8.  Összefoglalás 
A krónikus szívelégtelenséghez gyakran társulnak szívritmuszavarok és ez fordítva is 
igaz. A gyors ritmuszavarok nem-gyógyszeres kezelésének stabil alapjai vannak mind 
szupraventrikuláris, mind kamrai ritmuszavarok esetén krónikus szisztolés 
szívelégtelenség fennállása esetén is.  A gyors szívritmuszavarok ablációs- illetve 
ritmusszabályozó eszközös kezelésével nemcsak életminőség javulás érhető el, hanem 
sokszor a szisztolés diszfunkció progressziója és a káros bal kamrai szerkezeti átépülés 
is megfordítható. Munkatársaimmal bebizonyítottuk, hogy mind a kapcsolt mind a páros 
kamrai ingerlés képes hatékonyan és gyorsan csökkenteni a pulzusszámot gyors 
átvezetésű pitvarfibrilláció esetén. A kapcsolt kamrai ingerlésnek kevesebb proaritmiás 
hatása van. Elsőként igazoltuk, hogy a maximális feszültség vezérelt cavo-tricuspidalis 
isthmus ablációs technika hatékonyan kivitelezhető fennálló pitvarlebegés esetén is. A 
módszer segítségével szignifikánsan csökkenthető a procedúra idő is, mely különösen 
fontos szívelégtelenségben szenvedő betegek esetén. Elsőként mutattunk rá, hogy az 
ortotóp szívtranszplantáció során gyakran fordulhat elő a kéttekercses ICD 
sokkelektródák nem teljes eltávolítása. Ennek a műtéti szövődménynek nagy 
valószínűséggel elektróda tervezési probléma áll a hátterében. Szívtranszplantáció során 
nagyon fontos az ICD rendszer teljes eltávolítására törekedni, mivel az esetlegesen 
hátrahagyott fragmentumok később problémát okozhatnak az immunszupprimált 
betegekben. Szívtranszplantációra váró betegekben az egytekercses sokkelektródák 
használatát preferáljuk. A szív reszinkronizációs kezelésben részesülő betegek túlélését 
társbetegségeik is jelentősen korlátozhatják. 2009-ben elvégzett retrospektív 
vizsgálatunk igazolta, hogy a krónikus veseelégtelenség megléte extra halálozási rizikót 
hordoz és ez az emelkedett rizikó nem csökkenthető az ebben a csoportban gyakrabban 
alkalmazott ICD-k (CRT-D) segítségével sem. A súlyos társbetegségek 
reszinkronizációs kezelés előtti ismeretét külön kihangsúlyozza a 2013-ban kiadott 
európai pacemaker és reszinkronizációs kezelési irányelv, amely krónikus 
veseelégtelenség fennállása esetén inkább a CRT-P kezelést javasolja a CRT-D-vel 
szemben primer prevenciós indikáció esetén. 
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